IP Library Granted Patent US 9,913,849
Granted Patent B2
US 9,913,849 · App. 15/110,295 · Granted Mar 13, 2018

Treatment of migraines

Inventors: Robert L. Bratzler (Concord, MA); Martin Wand (Farmington, CT); Frederick Ryckman (West Chester, OH); Bradford J. Shingleton (Boston, MA)
Assignee: Manistee Partners LLC
A61K31/5575A61K9/0014A61K9/0048
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,913,849
App. No.
15/110,295
Granted
Mar 13, 2018
Kind
B2
Abstract

Provided herein are prostaglandin F2alpha analog compositions and methods for treating migraines by topical administration. The method involves administering topically to a subject in need thereof a composition including a prostaglandin F2apha analog or pharmaceutically acceptable salt thereof, in an amount effective to treat migraine. The treatment may be administered prophylactically or therapeutically. Topical administration is to the epidermis, conjunctival surface or other mucous membranes, typically to a nail, the skin, the hair, the surface of the eye or the inner surface of the eyelid, and the like. The prostaglandin F2a analog can be latanoprost, isopropyl unoprostone, bimatoprost, travoprost, or tafluprost; or pharmaceutically acceptable salt thereof.

Claims (8)

1. A method of treating migraine in a subject in need thereof, the method comprising administering topically to a nail, skin, or hair of the subject a composition comprising a prostaglandin F 2α analog or pharmaceutically acceptable salt thereof, in an amount effective to treat migraine, wherein the prostaglandin F 2a analog is selected from the group consisting of: latanoprost, isopropyl unoprostone, bimatoprost, travoprost, and tafluprost; or pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the prostaglandin F 2α analog or pharmaceutically acceptable salt thereof is administered prophylactically.

3. The method of claim 1 , wherein the prostaglandin F 2α analog or pharmaceutically acceptable salt thereof is administered therapeutically.

4. The method of claim 1 , wherein the prostaglandin F 2α analog or pharmaceutically acceptable salt thereof is administered to a nail of the subject.

5. The method of claim 1 , wherein the prostaglandin F 2α analog or pharmaceutically acceptable salt thereof is administered to the skin of the subject.

6. The method of claim 1 , wherein the prostaglandin F 2α analog or pharmaceutically acceptable salt thereof is bimatoprost or a pharmaceutically acceptable salt thereof.

7. The method of claim 1 , wherein the prostaglandin F 2α analog or pharmaceutically acceptable salt thereof is bimatoprost, travoprost, or latanoprost or a pharmaceutically acceptable salt thereof.

8. The method of claim 1 , wherein the prostaglandin F 2α analog or pharmaceutically acceptable salt thereof is administered to the hair of the subject.

Assignments (2)
CHANGE OF NAME Recorded Apr 29, 2021
From: MANISTEE PARTNERS LLC
To: MANISTEE THERAPEUTICS, INC.
Reel/Frame 056097/0310 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2017
From: BRATZLER, ROBERT L.; WAND, MARTIN; RYCKMAN, FREDERICK; SHINGLETON, BRADFORD J.
To: MANISTEE PARTNERS LLC
Reel/Frame 041056/0182 →
Continuity (2)
Provisional Application 61925676 · Jan 10, 2014
Related Publication 20160324870A1 · Nov 10, 2016